Anika

Anika Reports First Quarter 2024 Financial Results

Retrieved on: 
水曜日, 5月 8, 2024
FDA, Anika, Surgeon, Elective surgery, PEEK, Webcast, EPS, Therapy, Type, Growth, Video game

BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024.

Key Points: 
  • Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance
    Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the midpoint
    BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2024.
  • Revenue in the first quarter of 2024 was $40.5 million, up 7% compared to $37.9 million in the first quarter of 2023.
  • As such, Anika expects revenue for fiscal year 2024 of $168 to $173 million, representing growth of 1% to 4% compared to 2023.
  • Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Wednesday, May 8, 2024, at 5:30 pm ET.

Anika Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
水曜日, 3月 13, 2024
Type, Growth, Webcast, PEEK, Sale, Acquisition, Pain management, MDR, Therapy, PMA, Rationalization, Workforce, Sports medicine, FDA, Anika, Elective surgery

BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Revenue in the fourth quarter of 2023 was $43.0 million, up 8% compared to $39.6 million in the fourth quarter of 2022.
  • Adjusted EBITDA1 was $5.8 million, compared to $1.4 million in the fourth quarter of 2022.
  • “We are pleased to report strong fourth quarter and full year results, including a record year in OA Pain Management.
  • In 2023, Anika launched multiple meaningful new products and made considerable progress addressing the new MDR regulatory requirements in Europe.

Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting

Retrieved on: 
火曜日, 2月 13, 2024
Motion, MD, PET, Materialise NV, Anika, Next Generation, Partnership, Physician, Surgeon, Shoulder, AIM, RSA, Annual general meeting, Elective surgery, Therapy, Hyaluronic acid, TSA, Patient, Histology, AAOS, Sports medicine, Integrity, Medicine, American Academy, Dentistry

BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced it is highlighting recently-launched products in high growth segments of joint preservation and restoration from its Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions businesses during the 2024 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting on February 13-15 in San Francisco, CA. Throughout the event, Anika will feature its differentiated shoulder portfolio including the recently launched Integrity Implant System for rotator cuff repair, RevoMotion Reverse Shoulder Arthroplasty (RSA) System with newly launched AIMTM (Anika Implant Management) surgical planning software, X-Twist Fixation System with biocomposite suture anchor, OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System, and many more of its early intervention orthopedic solutions, in booth #5145.

Key Points: 
  • “Anika is excited to highlight our recently launched Integrity Implant System, our newest regenerative hyaluronic acid (HA)-based scaffold for rotator cuff repair, and our X-Twist Fixation System with biocomposite suture anchor.
  • We have also enhanced our shoulder arthroplasty offerings with the launch of AIM, Anika Implant Management, for 3-D preoperative planning which is now available with both the RevoMotion Reverse Shoulder and OVOMotion Total Shoulder arthroplasty systems.
  • The RevoMotion Reverse Shoulder Arthroplasty System, with the industry’s smallest diameter threaded baseplate, offers surgeons and patients the ability to restore motion and preserve bone.
  • Several new Sports Medicine products will also be available in early 2024, including the ProPass™ Suture Passer, and other new shoulder instrumentation.

Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business

Retrieved on: 
木曜日, 11月 2, 2023
FDA, Anika, Elective surgery, Acquisition, Growth, Surgeon, Webcast, OSET, Rationalization, Therapy, Furniture, Video game, Reinsurance, Bookkeeping, Dentistry, Road

BEDFORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its third quarter ended September 30, 2023.

Key Points: 
  • Revenue in the third quarter of 2023 was $41.5 million, up 3% compared to $40.3 million in the third quarter of 2022.
  • Adjusted EBITDA2 was $4.7 million, compared to $4.1 million in the third quarter of 2022.
  • Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Thursday, November 2, 2023, at 5:30 pm ET.
  • A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website.

Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023

Retrieved on: 
火曜日, 10月 10, 2023
Therapy, Elective surgery, Pharmaceutical industry, Video game, Cryptocurrency, Anika

BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m.

Key Points: 
  • BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m.
  • ET to discuss its financial results and business highlights.
  • The conference call can be accessed by dialing 1-844-826-3035 (toll-free domestic) or 1-412-317-5195 (international) and providing the conference ID number 10182980.
  • An accompanying slide presentation also can be accessed via the Anika website.

AcuityMD Launches ‘Pipeline’ to Enable MedTech Commercial Teams to Forecast with Accuracy and Improve Sales Planning

Retrieved on: 
火曜日, 9月 26, 2023
Data Management, Technology, Professional Services, Health, General Health, Health Technology, Other Technology, Data Analytics, Software, Other Professional Services, Finance, Maintenance, Partnership, Surgeon, Health care, Desktop, CRMS, Risk, Medtech, Anika, Sales, Pipeline

AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, announced the launch of Pipeline , a new module that enables sales representatives to execute on prospects throughout the sales lifecycle, track progress, forecast accurately, and ultimately improve business planning to grow revenue.

Key Points: 
  • AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, announced the launch of Pipeline , a new module that enables sales representatives to execute on prospects throughout the sales lifecycle, track progress, forecast accurately, and ultimately improve business planning to grow revenue.
  • AcuityMD’s Pipeline solution addresses the challenges of the complex MedTech sales lifecycle.
  • Healthcare professionals (HCPs) use MedTech products in vastly different ways depending on various factors, such as product type, surgical procedure, clinical preference, patient characteristics, among others.
  • They expanded their partnership with AcuityMD as an early adopter of AcuityMD Pipeline, which brings opportunity capture and management to the unified platform.

Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting

Retrieved on: 
火曜日, 9月 19, 2023
ASC, Surgeon, Elective surgery, Anatomy, BMA, Bone marrow, Booth, Hyaluronic acid, Pain, RSA, Motion, OSET, Great scapular notch, Integrity, Patient, Risk, Annual general meeting, Faculty, FDA, Therapy, Outpatient surgery, Video game, Medical device, Tutoring, Anika

BEDFORD, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced the full market release of their RevoMotion Reverse Shoulder Arthroplasty System (RSA) at the 2023 Orthopaedic Summit (OSET) Annual Meeting on September 20-23 in Boston, MA. Throughout the event, Anika will feature the RevoMotion RSA as well as the recently cleared Integrity Implant System and the recently launched X-Twist Fixation System at Booth #304 and during various educational opportunities throughout the conference.

Key Points: 
  • Integrity has an innovative delivery and fixation system and has greater regenerative capacity compared to first generation collagen patches.
  • “The RevoMotion Reverse Shoulder Arthroplasty System fills a vital place in Anika’s shoulder arthroplasty portfolio, which now offers the full line of solutions to meet my patients’ needs,” said Christopher Baker, M.D., Florida Orthopaedic Institute, Tampa, Florida.
  • Furthermore, Anika will have the newly cleared Integrity Implant System available for preview and demonstration at the booth.
  • The Integrity Implant System was fully cleared by the FDA in August 2023 with market launch targeted for Q1-2024, view press release here .

Anika Reports Second Quarter 2023 Financial Results

Retrieved on: 
火曜日, 8月 8, 2023
Elective surgery, OSET, PMA, Acquisition, Integrity, Smith College commencement controversies, Orthopedic surgery, Webcast, Growth, FDA, Therapy, 2023 Copa Libertadores qualifying stages, Video game, Airline, Car rental, Pharmaceutical industry, Anika

BEDFORD, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its second quarter ended June 30, 2023.

Key Points: 
  • Revenue in the second quarter of 2023 was $44.3 million, up 12% compared to $39.7 million in the second quarter of 2022.
  • Adjusted EBITDA2 was $6.3 million, compared to $4.4 million in the second quarter of 2022.
  • Ending cash balance was $65.1 million, after $5.0 million used to repurchase shares of Anika stock in the second quarter.
  • Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Tuesday, August 8, 2023, at 5:00 pm ET.

Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Retrieved on: 
木曜日, 7月 20, 2023
Therapy, Elective surgery, Cryptocurrency, Video game, Anika

BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2023 financial results after the close of the market on Tuesday, August 8, 2023 and hold its investor conference call on the same day, at 5:00 p.m.

Key Points: 
  • BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2023 financial results after the close of the market on Tuesday, August 8, 2023 and hold its investor conference call on the same day, at 5:00 p.m.
  • ET to discuss its financial results and business highlights.
  • The conference call can be accessed by dialing 1-888-886-7786 (toll-free domestic) or 1-416-764-8658 (international) and providing the conference ID number 87907131.
  • An accompanying slide presentation also can be accessed via the Anika website.

Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting

Retrieved on: 
水曜日, 7月 12, 2023
Osteoporotic bone marrow defect, Theatre, Sports medicine, Surgeon, Ochsner Health System, BMA, Torque, CableACE Award, New York Latin ACE Awards, RSVP, Pain, American Orthopaedic Society for Sports Medicine, Regeneration, Cyst, MD, Patient, Risk, Injury, ACE, Annual general meeting, Marrow, Expert, Joint, Therapy, TSA, Cutting edge, Anika, Video game, Dentistry, Medical imaging

BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced it will highlight core products from its joint preservation and restoration portfolio at the 2023 American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting on July 13-16th in Washington, D.C. As Anika continues to establish itself as a global market leader in joint preservation, the company will feature its Tactoset Injectable Bone Substitute for hardware augmentation, the X-Twist Fixation System, and the OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System at booth #311 during the conference.

Key Points: 
  • “We are excited to once again be joining the sports medicine community at the 2023 AOSSM Annual Meeting.
  • Anika’s focused and differentiated product portfolio in sports medicine with regenerative solutions continues to expand to best address the ever-evolving needs of surgeons and their patients.
  • Dr. Misty Suri is scheduled to present his postoperative data on Tactoset during the 2023 AOSSM Annual Meeting.
  • Throughout the 2023 AOSSM Annual Meeting, there will be ample opportunities to learn more about Anika’s featured products at the Anika booth #311 through Ask the Expert sessions.